 The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex MCC in patients with non-muscle invasive transitional cell carcinoma papillary tumors andor carcinoma in situ of the urinary bladder at high risk of progression who are refractory to therapy with bacillus Calmette-Guerin BCG. 